ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, PROTACs synthesized with bosutinib and dasatinib as BCR-ABL ligands can degrade BCR-ABL [161], facilitating the treatment of chronic myeloid leukemia (CML) caused by BCR-ABL structural proteins.